Ixazomib (Ninlaro,Isadx)

Ixazomib is a targeted anticancer drug that controls cancer cell growth by reversibly inhibiting the function of the proteasome.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Ixazomib Drug News

FDA Approves Ninlaro (ixazomib) for Multiple Myeloma

Approval AnnouncementNovember 20, 2015 -- Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two ···【More】
Update: 18 Mar,2026Source: BigbearViews: 113
First-Line Maintenance Therapy with Ixazomib, a Novel Multiple Myeloma Drug, Significantly Prolongs

Study Overview and Release ContextTakeda Pharmaceutical Company Limited, a Japanese pharmaceutical enterprise, recently announced the results of two c···【More】
Update: 18 Mar,2026Source: BigbearViews: 102

Bigbear Pharmaceutical